739 related articles for article (PubMed ID: 28412770)
21. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis.
Fukuta H; Hagiwara H; Kamiya T
PLoS One; 2022; 17(9):e0275311. PubMed ID: 36170343
[TBL] [Abstract][Full Text] [Related]
22. Anemia of chronic kidney disease: Treat it, but not too aggressively.
Nakhoul G; Simon JF
Cleve Clin J Med; 2016 Aug; 83(8):613-24. PubMed ID: 27505883
[TBL] [Abstract][Full Text] [Related]
23. Anemia management in chronic kidney disease and dialysis: a narrative review.
Collister D; Rigatto C; Tangri N
Curr Opin Nephrol Hypertens; 2017 May; 26(3):214-218. PubMed ID: 28306566
[TBL] [Abstract][Full Text] [Related]
24. Anemia in conventional hemodialysis: Finding the optimal treatment balance.
Hasegawa T; Koiwa F; Akizawa T
Semin Dial; 2018 Nov; 31(6):599-606. PubMed ID: 29909605
[TBL] [Abstract][Full Text] [Related]
25. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression?
Malyszko J; Glowinska I; Mysliwiec M
Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016
[TBL] [Abstract][Full Text] [Related]
26. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
Piotr B; Mariusz S; Jacek R
Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
[TBL] [Abstract][Full Text] [Related]
27. Importance of Physiological Erythropoiesis in the Treatment of Chronic Kidney Disease-Associated Anemia.
Kuragano T; Nakanishi T
Contrib Nephrol; 2018; 196():52-57. PubMed ID: 30041204
[TBL] [Abstract][Full Text] [Related]
28. Renal anemia: current treatments and emerging molecules.
Heras-Benito M
Rev Clin Esp (Barc); 2023; 223(7):433-439. PubMed ID: 37348652
[TBL] [Abstract][Full Text] [Related]
29. Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
Kile M; Sudchada P
Int Urol Nephrol; 2021 Feb; 53(2):283-290. PubMed ID: 32770437
[TBL] [Abstract][Full Text] [Related]
30. Anemia management in cancer patients with chronic kidney disease.
Deak AT; Troppan K; Rosenkranz AR
Eur J Intern Med; 2016 Dec; 36():13-19. PubMed ID: 27640913
[TBL] [Abstract][Full Text] [Related]
31. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?
Locatelli F; Del Vecchio L
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):339-344. PubMed ID: 29846220
[TBL] [Abstract][Full Text] [Related]
32. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
[TBL] [Abstract][Full Text] [Related]
33. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL
BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294
[TBL] [Abstract][Full Text] [Related]
34. An economic evaluation of erythropoiesis-stimulating agents in CKD.
Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
[TBL] [Abstract][Full Text] [Related]
35. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
Sugahara M; Tanaka T; Nangaku M
Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
[TBL] [Abstract][Full Text] [Related]
36. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Drug Saf; 2016 Aug; 15(8):1021-30. PubMed ID: 27149639
[TBL] [Abstract][Full Text] [Related]
37. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Matsui A; Hirakata H
Am J Nephrol; 2019; 49(2):165-174. PubMed ID: 30699415
[TBL] [Abstract][Full Text] [Related]
38. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
39. New strategies for managing anemia of chronic kidney disease.
Schmid H; Schiffl H; Lederer SR
Cardiovasc Hematol Agents Med Chem; 2012 Dec; 10(4):339-51. PubMed ID: 22642238
[TBL] [Abstract][Full Text] [Related]
40. Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study.
Tanaka S; Kitamura H; Tsuruya K; Kitazono T; Nakano T;
Clin Exp Nephrol; 2022 Sep; 26(9):867-879. PubMed ID: 35507237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
